About Prostacyclin receptor
Prostacyclin receptor (PTGIR) is a protein
from Homo sapiens identified by UniProt accession
P43119, 386 residues long.
MolForge cross-references it against 0 known binders and
130 disease associations.
Target properties
| Protein name | Prostacyclin receptor |
| UniProt accession | P43119 |
| Gene | PTGIR |
| Organism | Homo sapiens |
| Length | 386 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (10)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (130)
Diseases linked to this target (Open Targets).
- pulmonary arterial hypertension · score 0.61
- pulmonary hypertension · score 0.59
- Recurrent thrombophlebitis · score 0.53
- neurodegenerative disease · score 0.47
- cardiovascular disease · score 0.46
- heart failure · score 0.46
- chronic obstructive pulmonary disease · score 0.40
- idiopathic pulmonary arterial hypertension · score 0.37
- type 2 diabetes mellitus · score 0.37
- peripheral arterial disease · score 0.37
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P43119-F1 | alphafold | PREDICTED | 76.19 | — |
Amino-acid sequence (386 residues)
MADSCRNLTY VRGSVGPATS TLMFVAGVVG NGLALGILSA RRPARPSAFA VLVTGLAATD LLGTSFLSPA VFVAYARNSS LLGLARGGPA LCDAFAFAMT FFGLASMLIL FAMAVERCLA LSHPYLYAQL DGPRCARLAL PAIYAFCVLF CALPLLGLGQ HQQYCPGSWC FLRMRWAQPG GAAFSLAYAG LVALLVAAIF LCNGSVTLSL CRMYRQQKRH QGSLGPRPRT GEDEVDHLIL LALMTVVMAV CSLPLTIRCF TQAVAPDSSS EMGDLLAFRF YAFNPILDPW VFILFRKAVF QRLKLWVCCL CLGPAHGDSQ TPLSQLASGR RDPRAPSAPV GKEGSCVPLS AWGEGQVEPL PPTQQSSGSA VGTSSKAEAS VACSLC
Explore Prostacyclin receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets